linjc16/ctgov huggingface dataset:
A Comparative Trial of Valacyclovir Hydrochloride ( 256U87 ) and Acyclovir for the Suppression of Anogenital Herpes Infections in HIV-Infected Patients

Study Overview
=================
Brief Summary
-----------------
To determine the safety and efficacy of oral valacyclovir hydrochloride ( 256U87 ) compared to acyclovir in the treatment of recurrent anogenital herpes in HIV-infected patients with CD4 counts = or > 100 cells/mm3.

Official Title
-----------------
A Comparative Trial of Valacyclovir Hydrochloride ( 256U87 ) and Acyclovir for the Suppression of Anogenital Herpes Infections in HIV-Infected Patients

Conditions
-----------------
Herpes Simplex, HIV Infections

Intervention / Treatment
-----------------
* Drug: Valacyclovir hydrochloride
* Drug: Acyclovir


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria Patients must have: HIV infection with CD4 counts = or > 100 cells/mm3. Documented culture of anogenital herpes simplex virus (HSV) within the last 5 years. History of recurrent anogenital HSV infection, with a recurrence (with or without culture) within 1 year prior to study. Exclusion Criteria Co-existing Condition: Patients with the following symptoms and conditions are excluded: Malabsorption or vomiting that would potentially limit the retention and absorption of oral therapy. Concurrent Medication: Excluded: Systemic antiherpes medication. Interferon. Patients with the following prior conditions are excluded: History of hypersensitivity to acyclovir.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Valacyclovir hydrochloride|nan|
|Drug: Acyclovir|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Acyclovir, Acquired Immunodeficiency Syndrome, AIDS-Related Complex, Antiviral Agents, Anus Diseases, Herpes Genitalis
Pharmacodynamic Study of Carvedilol Versus Metoprolol in Heart Failure

Study Overview
=================
Brief Summary
-----------------
Metoprolol succinate is a beta1-selective beta-blocker, becoming non-selective at higher doses, while carvedilol is non-selective. We examined whether metoprolol remained beta1-selective compared to carvedilol during dose up-titration in Class C heart failure (HF) Beta-blocker naïve patients. METHODS: Twenty-five NYHA FC II-III HF patients were randomized to carvedilol or metoprolol. Patients were studied at baseline and after 2 weeks of up-titration (metoprolol at 25, 50, 100, and 200 mg daily; carvedilol IR at 3.125, 6.25, 12.5, 25 mg and 50mg twice daily). Beta2- blockade was determined by an infusion of terbutaline at 6 mg/kg over 1 hour. Glucose and potassium levels were serially measured at baseline, every 15 minutes for the 1st hour and 30 minutes for 2nd hour post-infusion. The median area under the curve (AUC) for glucose and potassium changes were calculated.

Official Title
-----------------
Beta-Receptor SELECTivity of Carvedilol and Metoprolol Succinnate in Patients With Heart Failure: A Randomized Dose Ranging Trial (SELECT Trial)

Conditions
-----------------
Heart Failure

Intervention / Treatment
-----------------
* Drug: Terbutaline Infusion


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients eligible for the study had objective evidence of systolic dysfunction (ejection fraction ≤40%), were >18 years of age, and were on stable optimal medical heart failure therapy excluding the use of beta-blockers within the previous 30 days. Exclusion Criteria: . Patients were excluded for active viral myocarditis; hemodynamically significant valvular heart disease; hypertrophic cardiomyopathy, peripartum cardiomyopathy; contra-indications to beta-blockers (asthma or obstructive airway disease requiring scheduled bronchodilators or inhaled steroids), resting heart rate <55; supine blood pressure <85/50; second or third degree heart block); concomitant use of beta-agonists, beta-antagonists, or anti-arrhythmics; unstable angina; myocardial infarction or bypass surgery within 3 months; or significant renal insufficiency (creatinine >2.5 mg/dL), liver disease (transaminase levels > 3 fold above laboratory normal), or anemia.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: 1<br>Carvedilol IR | Drug: Terbutaline Infusion<br> <br> |
| Active Comparator: 2<br>Metoprolol Succinate | Drug: Terbutaline Infusion<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Influencing Factors of Cerebrovascular Disease and Cognition in Hemodialysis Patients

Study Overview
=================
Brief Summary
-----------------
In this observational study, the investigators evaluate the influencing factors of cerebrovascular disease and cognition in hemodialysis patients.

Official Title
-----------------
Influencing Factors of Cerebrovascular Disease and Cognition in Hemodialysis Patients: an Observational Study

Conditions
-----------------
Hemodialysis, Cognitive Impairment, Cerebrovascular Disorders

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: maintenance hemodialysis patients who are younger than 85 years old and older than 50 years old, regardless of gender dialysis vintage is greater than 3 months; Exclusion Criteria: Those with severe infection and anemia (Hb <60g / L); Those with severe mental illness, metabolic diseases and immune system diseases; Patients with abnormal liver function

Ages Eligible for Study
-----------------
Minimum Age: 50 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| cerebrovascular disease | Magnetic resonance images will be used to determine the severity of white matter hyperintensity, using the Scheltens scale. Score 2 or more is abnormal. | 5 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| changes in cognitive function | The Mini-Mental State Examination (MMSE) will be used to assess the changes in cognitive function.The MMSE has a maximum score of 30 points. The scores are generally grouped as follows: 25-30 points: normal cognition 21-24 points: mild dementia 10-20 points: moderate dementia 9 points or lower: severe dementiaThe Mini-Mental State Examination (MMSE) will be used to assess the changes in cognitive function.The MMSE has a maximum score of 30 points. The scores are generally grouped as follows: 25-30 points: normal cognition 21-24 points: mild dementia 10-20 points: moderate dementia 9 points or lower: severe dementia | 5 years |
Study Comparing Blood Levels of ReFacto and Advante in Hemophilia A

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to compare the pharmacokinetic parameters of ReFacto and Advate, using the chromogenetic substrate assay to measure plasma Factor VIII activity in plasma.

Official Title
-----------------
A Single Dose, Randomized, 2-Period Crossover Study in Patients With Hemophilia A to Evaluate the Pharmacokinetics of ReFacto (B-domain Deleted Recombinant Human Factor VIII (BDDrFVIII) and Advante (a Full-length Recombinant Factor VIII (FLrFVIII)

Conditions
-----------------
Hemophilia A

Intervention / Treatment
-----------------
* Drug: ReFacto
* Drug: Advante


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Severe hemophilia A Previously treated patients with at least 150 exposure days to any Factor VIII product Exclusion Criteria: Hypersensitivity to any recombinant Factor VIII product History of or current Factor VIII inhibitor Bleeding episode or other reason requiring Factor VIII treatment within 3 days of study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 64 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: ReFacto|nan|
|Drug: Advante|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pharmacokinetic measurement of area under the plasma Factor VIII activity in plasma versus time curve for 48 hours. |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of subjects who experience any adverse event or develop Factor VIII inhibitor at study termination, 48 hours post dosing and/or at the final study visit within seven days of the 2nd period of the study. |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Hemophilia A
Correlations Between Lens Star and Phacoemulsification.

Study Overview
=================
Brief Summary
-----------------
To assess correlations between lens star biometry parameters and phacoemulsification in clinical practice.

Detailed Description
-----------------
To analyze possible correlations between lens star biometry parameters and phacoemulsification in mild to moderate senile cataract.

Official Title
-----------------
Correlations Between Lens Star Parameters and Phacoemulsification in Clinical Practice.

Conditions
-----------------
Cataract, Lens Diseases, Lens Opacities

Intervention / Treatment
-----------------
* Device: Phacoemulsification


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients that will undergone phacoemulsification for their mild to moderate senile cataracts. Exclusion Criteria: congenital and developmental cataract. cases with congenital lens anomalies as ectopia lentis and spheophakia.

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Interventional Model Description: Senile cataract patients
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Lens star biometry<br>Biometry done prior to phacoemulsification | Device: Phacoemulsification<br>* Phacoemulsification for senile cataract.<br>* Other names: Phaco;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Correlation between parameters measured by lens star. | Anterior chamber depth, lens, axial length, keratometry readings and age of the patients. | Immediately before phacoemulsification surgery | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Cataract
Effect of Low-level Laser Therapy During Maxillary Molar Distalization Using a Skeletally Anchored Appliance

Study Overview
=================
Brief Summary
-----------------
study will be directed to evaluate the effect of low-level laser therapy during maxillary molar distalization using a skeletally anchored appliance

Detailed Description
-----------------
Effect of low-level laser therapy during maxillary molar distalization using a skeletally anchored appliance

Official Title
-----------------
Effect of Low-level Laser Therapy During Maxillary Molar Distalization Using a Skeletally Anchored Appliance: A Prospective Clinical Study

Conditions
-----------------
Class II Division 1 Malocclusion

Intervention / Treatment
-----------------
* Other: Distalization


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 1- An age range from 14-17 years old. 2- All permanent teeth are present (except for third molars). 3- Bilateral dental Class II malocclusion. 4- Skeletal Class I or mild Class II relationship. 5- Normal or reduced vertical face height. 6- No posterior crowding or spaces. Exclusion Criteria: Patients who required surgery to correct skeletal discrepancies. Patients with congenital dentoskeletal disorders. Missed or mutilated teeth in maxillary arch. Patients with poor oral hygiene and/or periodontally compromised patients.

Ages Eligible for Study
-----------------
Minimum Age: 14 Years
Maximum Age: 17 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Group I<br>will include 10 patients undergo distalization according to a standardized protocol | Other: Distalization<br>* Group I: will include 10 patients undergo distalization according to a standardized protocol. Group II: will include 10 patients undergo distalization assisted with low level laser therapy according to a standardized protocol.<br>|
| Active Comparator: Group II<br>will include 10 patients undergo distalization assisted with low level laser therapy according to a standardized protocol | Other: Distalization<br>* Group I: will include 10 patients undergo distalization according to a standardized protocol. Group II: will include 10 patients undergo distalization assisted with low level laser therapy according to a standardized protocol.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| rate of molar distalization | rate of distalization of the maxillary first molars will be evaluated using direct clinical assessment and cast analysis according to standardized methods. | from start of treatment until study completion, an average of 1 year |
Comparison of a Spectral OCT/SLO With the Stratus OCT for Imaging Various Retinal Pathologies

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to compare the newly released Spectral OCT/SLO (OTI, Toronto, Canada) with the Zeiss Stratus OCT (Carl-Zeiss Meditec, Dublin, CA) with regards to the quality of the images obtained as well as the ease of use.

Official Title
-----------------
Comparison of a Spectral OCT/SLO With the Stratus OCT for Imaging Various Retinal Pathologies

Conditions
-----------------
Macular Hole, RPE Detachment, Epiretinal Membrane, Posterior Vitreous Detachment

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: N/A Exclusion Criteria: N/A

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 95 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Spectral OCT, SLO, Retinal Imagining
A Study on a New Staining Method (C4d Staining) of Transplanted Kidney Biopsies

Study Overview
=================
Brief Summary
-----------------
Patients who had received kidney transplantation may suffer from rejection. Recently, positive staining for C4d in kidney biopsies of malfunctioning transplant kidney is increasingly recognized as an important prognostic indicator of poorer long-term kidney outcome. Data is, however, lacking in Hong Kong.

Official Title
-----------------
Experience of C4d Staining in Renal Allograft Biopsies

Conditions
-----------------
Kidney Transplantation, Graft Rejection

Intervention / Treatment
-----------------
* Procedure: Renal biopsy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All renal allograft biopsies performed in Princess Margaret Hospital (PMH) during the period 1st April 2003 to 31st August 2005 for unexplained acute renal dysfunction (Creatinine rise from baseline by ≥ 20%) or delayed graft function in the immediate post-transplantation period were included in the study. Both cadaveric and living-donor transplant allografts were included. Exclusion Criteria: patients who were < 18 years' old at the time of renal biopsy or whose records were so incomplete that preclude meaningful analysis

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Renal biopsy|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Delayed renal graft function, Acute renal allograft dysfunction
Developing Models for Fatigue Monitoring in Obstetrics and Gyne- Cology Residents Using Wearables

Study Overview
=================
Brief Summary
-----------------
This study is set out to observe heart-rate and related bio-metric indicators in Obstetrics and Gynecology residents during their duty hours, together with self-reporting of fatigue and tasks performances, in order to model possible relationships between the two.

Detailed Description
-----------------
There are vast evidences of the harmful consequences of fatigue in medical residents, consequently, leading to poor task performances and in some cases may cause injury to the patients. Medically, fatigue is a non-specific symptom, which means that it has many possible causes and accompanies many different conditions. Elevated fatigue is an indication that a person may not be fit-to-task (i.e., task efficacy).The investigators main goal is to use readily available body-worn sensors, such as an activity wrist-band, to continuously monitor for fatigue as a possible antecedent to predictions of task-efficacy in the area of Obstetrics and Gynecology. This study is anchored in prior research which established basic models that correlate between heart-rate variability (HRV) and fatigue. Specific to this study, the investigators would like to further establish the validity of such models at the individual level, also with the perspective of fatigue as an early predictor of task performance related to practices in Obstetrics and Gynecology. The investigators aim is to extend HRV based models with additional personal measures (e.g., age, weight, activity level), possibly with the extraction of additional data-driven features, to improve model accuracy at the individual level. The investigators will also try to find relationships between such measurements and task effectiveness via the gathering of self-reports regarding on-the-job task performances.

Official Title
-----------------
Developing Models for Fatigue Monitoring in Obstetrics and Gyne- Cology Residents Using Wearables

Conditions
-----------------
Fatigue

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Participants will be chosen from the obstetrics and gynecology department in the Hillel Yaffe medical center. Exclusion Criteria: Chronic fatigue syndrome Pregnancy
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Fatigue determination model. | A model for detecting abnormal fatigue alert. | Through study completion, an average of 1 year. | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Fatigue based fit-to-task model. | Model for estimation of for seen task performance. | Through study completion, an average of 1 year. |